NewAmsterdam Pharma (NASDAQ:NAMS) Director Louis Lange Sells 44,619 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director Louis Lange sold 44,619 shares of the business’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $30.42, for a total transaction of $1,357,309.98. Following the transaction, the director directly owned 10,360 shares in the company, valued at approximately $315,151.20. The trade was a 81.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

NewAmsterdam Pharma Stock Down 0.7%

Shares of NASDAQ:NAMS traded down $0.21 on Friday, hitting $29.61. The company had a trading volume of 260,399 shares, compared to its average volume of 759,975. The firm’s 50-day simple moving average is $33.24 and its two-hundred day simple moving average is $33.32. The firm has a market capitalization of $3.40 billion, a price-to-earnings ratio of -17.09 and a beta of 0.04. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.92 million. Equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on NAMS shares. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Stifel Nicolaus increased their price objective on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Royal Bank Of Canada raised their price objective on NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Guggenheim boosted their target price on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.10.

Institutional Trading of NewAmsterdam Pharma

Institutional investors have recently bought and sold shares of the company. Atle Fund Management AB increased its position in shares of NewAmsterdam Pharma by 23.2% during the third quarter. Atle Fund Management AB now owns 193,625 shares of the company’s stock valued at $5,507,000 after acquiring an additional 36,402 shares in the last quarter. Jennison Associates LLC lifted its position in NewAmsterdam Pharma by 42.5% in the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after acquiring an additional 1,252,451 shares in the last quarter. Capital World Investors lifted its position in NewAmsterdam Pharma by 17.1% in the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after acquiring an additional 1,434,986 shares in the last quarter. Keybank National Association OH purchased a new stake in NewAmsterdam Pharma during the 3rd quarter valued at $455,000. Finally, Franklin Resources Inc. boosted its stake in NewAmsterdam Pharma by 30.6% during the 2nd quarter. Franklin Resources Inc. now owns 334,212 shares of the company’s stock valued at $6,053,000 after purchasing an additional 78,300 shares during the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.